Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052143 · ClinicalTrials.gov registry record
Prospective Huntington At Risk Observational Study
A clinical trial of Huntington Disease, sponsored by Huntington Study Group.
- Completed
- Registry status
- 1,001
- Enrollment target
- 20
- Study locations
NCT00052143: Completed study of Huntington Disease, sponsored by Huntington Study Group.
NCT00052143 is a study of Huntington Disease that has completed, run by Huntington Study Group. The registered enrollment target is 1,001 participants, above the 607-participant average among 35 other Huntington Disease trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00052143, a study of Huntington Disease, has completed, sponsored by Huntington Study Group.
- COMPLETED
- Registry status
- 1,001 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to define the natural history and experiences of people who are at risk for developing Huntington's disease but who do not know their genetic status.
Conditions Studied
Study Locations (20)
California
- University of California at San Diego - La Jolla
- UCLA School of Medicine - Los Angeles
- University of California, Davis - Sacramento
Connecticut
- University of Connecticut - Hartford
- Institute for Neurodegenerative Disorders - New Haven
Florida
- University of Miami School of Medicine - Miami
- University of South Florida - Tampa
Kansas
- University of Kansas Medical Center - Kansas City
- Hereditary Neurological Disease Center - Wichita
Maryland
- Johns Hopkins University - Baltimore
- University of Maryland at Baltimore - Baltimore
Massachusetts
- Boston University School of Medicine - Boston
- Massachusetts General Hospital - Boston
Alabama
- University of Alabama - Birmingham
Arizona
- Mayo Clinic Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,001 participants |
| Start Date | 1999-07-09 |
| Est. Completion | 2009-12-17 |
What the finished NCT00052143 record still lists
NCT00052143 is an observational study that tracks outcomes without assigning an intervention. Its 1,001 participants enrollment target places it among the larger protocols in the corpus, above the 607-participant average among 35 other Huntington Disease trials with a reported enrollment target (65% higher).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 0 interventions.
NCT00052143 names 20 study sites across 13 states, led by California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT00052143 about?
NCT00052143 is a clinical study titled "Prospective Huntington At Risk Observational Study". The purpose of this study is to define the natural history and experiences of people who are at risk for developing Huntington's disease but who do not know their genetic status.
What is the current status of trial NCT00052143?
This trial is currently completed. The enrollment target is 1,001 participants. The study started on 1999-07-09. Estimated completion is 2009-12-17.
What conditions does trial NCT00052143 study?
This clinical trial studies the following conditions: Huntington Disease.
Who is sponsoring clinical trial NCT00052143?
This trial is sponsored by Huntington Study Group, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00052143 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00052143's enrollment target sits among peer trials
1,001 5th of 35 higher than 31 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI